Vireo Growth (VREOD) Stock Price, News & Analysis

Company Overview

Vireo Growth is a cannabis-focused company that develops and operates licensed cannabis cultivation, processing, and retail businesses in the United States. The company’s activities generally center on producing and distributing cannabis products for both medical and adult-use markets, depending on the laws of the states in which it operates.

Vireo Growth has pursued a multi-state strategy, with operations historically concentrated in select U.S. markets where cannabis is legal under state law. Its business has typically included flower, pre-rolls, edibles, and other cannabis-derived products sold through its own retail locations and wholesale channels, as well as through third-party dispensaries where permitted.

As with many cannabis companies, Vireo Growth’s footprint and business priorities have evolved over time in response to changes in state regulations and market conditions. For the most current information on its leadership, operational scope, and geographic presence, investors should refer to the company’s latest corporate filings and public disclosures.

Key Stats

• Today's Range: $9.95 to $9.95
• 50-Day Range: $9.56 to $13.50
• 52-Week Range: $8.91 to $24.00
• Volume: N/A
• Average Volume: 14,588 shs
• Market Capitalization: $450.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Vireo Growth Stock Analysis - MarketRank™

Vireo Growth scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Vireo Growth has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Vireo Growth has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 200.00%

Earnings Growth

Earnings for Vireo Growth are expected to grow by 200.00% in the coming year, from $0.30 to $0.90 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vireo Growth is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vireo Growth is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vireo Growth has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Vireo Growth has been sold short.

Short Interest Ratio / Days to Cover

Vireo Growth has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vireo Growth has recently decreased by 97.85%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vireo Growth does not currently pay a dividend.

Dividend Growth

Vireo Growth does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.95

News Sentiment

Vireo Growth has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Vireo Growth this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vireo Growth insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.80% of the stock of Vireo Growth is held by insiders.

Percentage Held by Institutions

Vireo Growth has minimal institutional ownership at this time.

Company Calendar

• Today: 7/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:VREOD
• Previous Symbol: OTCMKTS:GDNSF
• CIK: 1771706
• Web: www.vireohealth.com
• Phone: (612) 999-1606
• Fax: N/A
• Employees: 500
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 33.17
• P/E Growth: N/A
• Net Income: -$68.11 million
• Net Margins: -23.37%
• Pretax Margin: -11.22%
• Return on Equity: -19.76%
• Return on Assets: -7.15%

Debt

• Debt-to-Equity Ratio: 0.70
• Current Ratio: 1.20
• Quick Ratio: 0.84

Sales & Book Value

• Annual Sales: $268.77 million
• Price / Sales: 1.68
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.73 per share
• Price / Book: 1.14

Miscellaneous

• Outstanding Shares: 45,315,000
• Free Float: 43,593,000
• Market Cap: $450.88 million
• Optionable: Not Optionable
• Beta: 1.78